Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solabegron - Velicept Therapeutics

Drug Profile

Solabegron - Velicept Therapeutics

Alternative Names: 427353; GW-427353; GW-427353B; Solabegron; Solabegron hydrochloride

Latest Information Update: 30 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer AltheRx; Velicept Therapeutics
  • Class Aniline compounds; Antihyperglycaemics; Benzoic acids; Obesity therapies; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome; Overactive bladder
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for preclinical development in Overactive bladder(Combination therapy) in USA (PO)
  • 02 May 2019 Velicept Therapeutics completes a phase II trial in Overactive bladder in USA (PO) in USA (NCT03594058)
  • 30 Jan 2019 Velicept Therapeutics completes a phase II trial in Overactive bladder in USA (NCT03475706)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top